Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation
NCT ID: NCT02784912
Last Updated: 2017-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2017-09-30
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to create a model of risk stratification to identify patients with increased risk of occurrence of composite (cardiovascular death or rehospitalization, arrhythmia recurrence) and secondary (inadequate device therapy, all-cause death or rehospitalization, intensification of atrial arrhythmia) endpoints after ablation of ES or sustained VT. Model will be based on additional measurements of N-terminal pro brain natriuretic peptide (NT-proBNP), Galectin-3, suppressor of tumorigenicity 2 (ST2), high sensitive troponin T (hs-TnT), high sensitive C-reactive protein (hs-CRP), iron deficiency to clinical-, electrocardiographic- and echocardiographic assessment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adenosine vs AF Termination for Paroxysmal AF Ablation
NCT02238392
Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation
NCT01505296
Burst Stimulation for Paroxysmal Atrial Fibrillation
NCT07281898
AF Ablation With High Power Short Duration RF
NCT05777551
A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy
NCT00773539
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Risk factors for recurrence of VA are difficult to identify, although there are mentioned e.g. reduced left ventricular ejection fraction, exacerbation of chronic HF and electrolyte abnormalities.
VA is triggered by ongoing inflammation and fibrosis, which are reflected by a level of biomarkers. Thus, it is worth searching for biomarkers that increase the possibility of effective stratification of risk of arrhythmia recurrence in patients undergoing ablation of sVT or ES.
The hypothesis of this study is that biomarker-related risk stratification may be beneficial for patients with ES or sVT.
Sample size assessment was made to specify the number of participants necessary to demonstrate an effect.
The study will include at least 50 patients (who meet the inclusion/exclusion criteria) with ischemic heart failure, with reduced left ventricle ejection fraction admitted to hospital and qualified for ablation due to ES or sVT.
For every patient will be provided case report forms (CRFs) including their clinical status at admission and at discharge, laboratory findings, management during index hospitalization, data from ablation procedure, pharmacotherapy, as well as in-hospital and one-year outcome.
Serum will be collected before ablation and 1-month after discharge from hospital for biomarkers measurements. Patients will be tele-monitored for ≥12-months. There will be carried out two control visits (including assessment of clinical, echocardiographic, electrocardiographic and Holter-ECG parameters) on 1- and 3 months after discharge.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed consent
* ischemic heart disease
* left ventricle ejection fraction \<= 35%
* admission to hospital due to electrical storm or sustained ventricular tachycardia and qualification for ablation of the arrhythmia
* patients with already implanted cardioverter defibrillator (ICD) / cardiac resynchronization therapy defibrillator (CRT-D) or patients qualified for implantation
Exclusion Criteria
* current ischemia and potentially reversible causes (e.g. electrolyte abnormalities, drug intoxication) of the arrhythmia
* congenital genetic heart disease
* serious comorbidities (e.g. neoplasm)
* chronic inflammatory disease (e.g. inflammatory bowel disease, rheumatoid arthritis)
* renal failure (creatinine \>2,5 mg/dl)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Warsaw
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marcin Grabowski
Clinical Professor, Marcin Grabowski, Medical University of Warsaw
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marcin D Grabowski, PhD
Role: STUDY_CHAIR
1st Department of Cardiology Medical University of Warsaw
Piotr Lodzinski, PhD
Role: STUDY_CHAIR
1st Department of Cardiology Medical University of Warsaw
Grzegorz Opolski, Professor
Role: STUDY_CHAIR
1st Department of Cardiology Medical University of Warsaw
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1st Department of Cariology of Medcial University of Warsaw
Warsaw, Masovian Voivodeship, Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STORM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.